JP2023513847A - 慢性移植片対宿主病の治療方法 - Google Patents

慢性移植片対宿主病の治療方法 Download PDF

Info

Publication number
JP2023513847A
JP2023513847A JP2022549737A JP2022549737A JP2023513847A JP 2023513847 A JP2023513847 A JP 2023513847A JP 2022549737 A JP2022549737 A JP 2022549737A JP 2022549737 A JP2022549737 A JP 2022549737A JP 2023513847 A JP2023513847 A JP 2023513847A
Authority
JP
Japan
Prior art keywords
cells
score
point
mlpscs
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513847A5 (https=
Inventor
シルヴィウ・イテスク
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900472A external-priority patent/AU2020900472A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2023513847A publication Critical patent/JP2023513847A/ja
Publication of JP2023513847A5 publication Critical patent/JP2023513847A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0669—Bone marrow stromal cells; Whole bone marrow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022549737A 2020-02-19 2021-02-18 慢性移植片対宿主病の治療方法 Pending JP2023513847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900472 2020-02-19
AU2020900472A AU2020900472A0 (en) 2020-02-19 Method for treating chronic graft versus host disease
PCT/EP2021/054066 WO2021165420A1 (en) 2020-02-19 2021-02-18 Method for treating chronic graft versus host disease

Publications (2)

Publication Number Publication Date
JP2023513847A true JP2023513847A (ja) 2023-04-03
JP2023513847A5 JP2023513847A5 (https=) 2024-02-29

Family

ID=74701467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549737A Pending JP2023513847A (ja) 2020-02-19 2021-02-18 慢性移植片対宿主病の治療方法

Country Status (9)

Country Link
US (1) US20230097931A1 (https=)
EP (1) EP4106776A1 (https=)
JP (1) JP2023513847A (https=)
KR (1) KR20220143092A (https=)
CN (1) CN115361960A (https=)
AU (1) AU2021222342A1 (https=)
BR (1) BR112022016448A2 (https=)
CA (1) CA3168330A1 (https=)
WO (1) WO2021165420A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501740A (ja) * 2013-11-04 2017-01-19 アイソポジェン ピーティーワイ リミテッド 細胞培養方法
WO2018202853A1 (en) * 2017-05-04 2018-11-08 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
KR20080105555A (ko) * 2007-05-31 2008-12-04 인하대학교 산학협력단 중간엽 골수세포를 이용한 이식편대숙주질환 치료제 및치료방법
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
EP2324109B1 (en) * 2008-09-03 2016-10-26 Mesoblast, Inc. Expansion of haemopoietic precursors
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501740A (ja) * 2013-11-04 2017-01-19 アイソポジェン ピーティーワイ リミテッド 細胞培養方法
WO2018202853A1 (en) * 2017-05-04 2018-11-08 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOL BLOOD MARROW TRANSPLANT, vol. 16, JPN6025013627, 2010, pages 403 - 412, ISSN: 0005567794 *
BIOL BLOOD MARROW TRANSPLANT, vol. 16, JPN6025013628, 2010, pages 1293 - 1301, ISSN: 0005567793 *

Also Published As

Publication number Publication date
BR112022016448A2 (pt) 2022-11-29
AU2021222342A1 (en) 2022-09-15
US20230097931A1 (en) 2023-03-30
EP4106776A1 (en) 2022-12-28
CN115361960A (zh) 2022-11-18
WO2021165420A1 (en) 2021-08-26
KR20220143092A (ko) 2022-10-24
CA3168330A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
JP2023513847A (ja) 慢性移植片対宿主病の治療方法
EP4125957A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20230104108A1 (en) Method for treating inflammatory bowel disease ii
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20230172991A1 (en) Method for treating inflammatory bowel disease i
US20240207323A1 (en) Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells
WO2023119239A1 (en) Method of treating severe graft versus host disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304